MDA Action Center

Welcome to the MDA Action Center, your destination for the most important scientific advances, clinical updates, and emerging themes presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. Designed for neurologists and healthcare professionals who care for individuals with neuromuscular diseases, this series distills high-impact sessions into clinically relevant insights you can apply in practice today.

1-6 of 6

Strengthening Global Infrastructure for FSHD Trials
Strengthening Global Infrastructure for FSHD Trials
AudioAbstracts
Strengthening Global Infrastructure for FSHD Trials
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
- Ryan Quigley
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen

MDA Action Center

1-6 of 6

NEED HELP?

Contact us

NEED HELP?

Contact us

1-6 of 6

Title